onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Company profile
Ticker
TRAW
Exchange
Website
CEO
Steven Fruchtman
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ONCONOVA THERAPEUTICS INC, Onconova Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Onconova Europe GmbH ...
TRAW stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
21 Jun 24
8-K/A
Financial Statements and Exhibits
17 Jun 24
8-K
Changes in Registrant's Certifying Accountant
22 May 24
8-K
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
16 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
D
$14.00 mm in other securities, sold $14.00 mm, 2 investors
16 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
8-K
Potential best in class p roduct candidates in development for cancer & respiratory viral diseases April 2024 NASDAQ - TRAW
16 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
Transcripts
TRAW
Earnings call transcript
2023 Q3
14 Nov 23
TRAW
Earnings call transcript
2023 Q2
10 Aug 23
TRAW
Earnings call transcript
2023 Q1
15 May 23
TRAW
Earnings call transcript
2022 Q4
16 Mar 23
TRAW
Earnings call transcript
2022 Q3
15 Nov 22
TRAW
Earnings call transcript
2022 Q2
12 Aug 22
TRAW
Earnings call transcript
2022 Q1
11 May 22
TRAW
Earnings call transcript
2021 Q4
18 Mar 22
TRAW
Earnings call transcript
2021 Q3
12 Nov 21
TRAW
Earnings call transcript
2021 Q2
12 Aug 21
Latest ownership filings
4
Mark Patrick Guerin
20 Jun 24
3/A
Initial statement of insider ownership (amended)
12 Apr 24
3/A
Initial statement of insider ownership (amended)
11 Apr 24
SC 13D
Viriom, Inc.
8 Apr 24
4
Robert Redfield
3 Apr 24
4
Charles David Pauza
3 Apr 24
4
WERNER CAUTREELS
3 Apr 24
4
Nikolay Savchuk
3 Apr 24
4
Iain D. Dukes
3 Apr 24
3
Initial statement of insider ownership
3 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.39 mm | 16.39 mm | 16.39 mm | 16.39 mm | 16.39 mm | 16.39 mm |
Cash burn (monthly) | 1.48 mm | 1.49 mm | 1.74 mm | 1.61 mm | 1.47 mm | 1.48 mm |
Cash used (since last report) | 4.12 mm | 4.15 mm | 4.85 mm | 4.50 mm | 4.11 mm | 4.14 mm |
Cash remaining | 12.27 mm | 12.24 mm | 11.54 mm | 11.89 mm | 12.28 mm | 12.25 mm |
Runway (months of cash) | 8.3 | 8.2 | 6.6 | 7.4 | 8.3 | 8.3 |
Institutional ownership, Q4 2023
54.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 26 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 30.59 mm |
Total shares | 13.67 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lincoln Park Capital Fund | 13.64 mm | $8.65 mm |
Hillcrest Wealth Advisors - NY | 16.72 k | $12.47 mm |
Mutual Advisors | 12.70 k | $9.47 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jun 24 | Guerin Mark Patrick | Common Stock | Payment of exercise | Dispose F | No | No | 0.47 | 2,221 | 1.04 k | 39,255 |
18 Jun 24 | Guerin Mark Patrick | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,500 | 0.00 | 5,500 |
10 Jun 24 | Guerin Mark Patrick | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,500 | 0.00 | 41,476 |
News
Traws Pharma Q1 EPS $(0.24) Up From $(0.28) YoY, Sales $56.00K, Same YoY
16 May 24
Traws Pharma Completes First Cohort Dosed In Phase 1 Trial For COVID Therapy
7 May 24
Earnings Scheduled For April 16, 2024
16 Apr 24
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
4 Apr 24
Press releases
Traws Pharma's ICAR Poster Highlights Potency of COVID-19 Candidate
23 May 24
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
16 May 24
Traws Pharma Announces New Employee Inducement Grants
2 Apr 24
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
2 Apr 24